Global Wet Age Related Macular Degeneration (AMD) Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Q: What are the significant segments operating in the market?

Market is segmented on the basis. Read More

Global Wet Age Related Macular Degeneration (AMD) Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Report ID : 282607
Published On: Mar, 2022
Pages: 156
Pharmaceuticals and Healthcare

Buy @ $3500

The Wet Age Related Macular Degeneration (AMD) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Wet Age Related Macular Degeneration (AMD) market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Above 75 Years accounting for % of the Wet Age Related Macular Degeneration (AMD) global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Wet Age-Related Macular Degeneration (Wet AMD) segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Wet Age Related Macular Degeneration (AMD) include Novartis International (Switzerland), Bayer (Germany), Acucela (US), Neurotech Pharmaceuticals (US), and Ophthotech (US), etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Wet Age Related Macular Degeneration (AMD) market is split by Type and by Age. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Age. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Wet Age-Related Macular Degeneration (Wet AMD)

Dry Age-Related Macular Degeneration (Dry AMD)

Market segment by Age, can be divided into

Above 75 Years

Above 60 Years

Above 40 Years

Market segment by players, this report covers

Novartis International (Switzerland)

Bayer (Germany)

Acucela (US)

Neurotech Pharmaceuticals (US)

Ophthotech (US)

GlaxoSmithKline (US)

Alimera Sciences (US)

StemCell (Canada)

F. Hoffmann-La Roche (Switzerland)

Regeneron Pharmaceutical (US)

Allergan (Ireland)

Adverum Biotechnologies (US)

Gilead Sciences (US)

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Wet Age Related Macular Degeneration (AMD) product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Wet Age Related Macular Degeneration (AMD), with revenue, gross margin and global market share of Wet Age Related Macular Degeneration (AMD) from 2019 to 2022.

Chapter 3, the Wet Age Related Macular Degeneration (AMD) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Wet Age Related Macular Degeneration (AMD) market forecast, by regions, type and age, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Wet Age Related Macular Degeneration (AMD) research findings and conclusion, appendix and data source.

Frequently Asked Questions

What is scope of the report?

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

What are the significant segments operating in the market?

Market is segmented on the basis:

By Type
By Application
By Region
By Country
By Manufacturer

What are the vital market dynamics?

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

What does a company profile includes?

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Wet Age Related Macular Degeneration (AMD)

1.2 Classification of Wet Age Related Macular Degeneration (AMD) by Type

1.2.1 Overview: Global Wet Age Related Macular Degeneration (AMD) Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Type in 2021

1.2.3 Wet Age-Related Macular Degeneration (Wet AMD)

1.2.4 Dry Age-Related Macular Degeneration (Dry AMD)

1.3 Global Wet Age Related Macular Degeneration (AMD) Market by Age

1.3.1 Overview: Global Wet Age Related Macular Degeneration (AMD) Market Size by Age: 2017 Versus 2021 Versus 2028

1.3.2 Above 75 Years

1.3.3 Above 60 Years

1.3.4 Above 40 Years

1.4 Global Wet Age Related Macular Degeneration (AMD) Market Size & Forecast

1.5 Global Wet Age Related Macular Degeneration (AMD) Market Size and Forecast by Region

1.5.1 Global Wet Age Related Macular Degeneration (AMD) Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Wet Age Related Macular Degeneration (AMD) Market Size by Region, (2017-2022)

1.5.3 North America Wet Age Related Macular Degeneration (AMD) Market Size and Prospect (2017-2028)

1.5.4 Europe Wet Age Related Macular Degeneration (AMD) Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size and Prospect (2017-2028)

1.5.6 South America Wet Age Related Macular Degeneration (AMD) Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Wet Age Related Macular Degeneration (AMD) Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Wet Age Related Macular Degeneration (AMD) Market Drivers

1.6.2 Wet Age Related Macular Degeneration (AMD) Market Restraints

1.6.3 Wet Age Related Macular Degeneration (AMD) Trends Analysis

2 Company Profiles

2.1 Novartis International (Switzerland)

2.1.1 Novartis International (Switzerland) Details

2.1.2 Novartis International (Switzerland) Major Business

2.1.3 Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Product and Solutions

2.1.4 Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Novartis International (Switzerland) Recent Developments and Future Plans

2.2 Bayer (Germany)

2.2.1 Bayer (Germany) Details

2.2.2 Bayer (Germany) Major Business

2.2.3 Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Product and Solutions

2.2.4 Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Bayer (Germany) Recent Developments and Future Plans

2.3 Acucela (US)

2.3.1 Acucela (US) Details

2.3.2 Acucela (US) Major Business

2.3.3 Acucela (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions

2.3.4 Acucela (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Acucela (US) Recent Developments and Future Plans

2.4 Neurotech Pharmaceuticals (US)

2.4.1 Neurotech Pharmaceuticals (US) Details

2.4.2 Neurotech Pharmaceuticals (US) Major Business

2.4.3 Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions

2.4.4 Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Neurotech Pharmaceuticals (US) Recent Developments and Future Plans

2.5 Ophthotech (US)

2.5.1 Ophthotech (US) Details

2.5.2 Ophthotech (US) Major Business

2.5.3 Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions

2.5.4 Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Ophthotech (US) Recent Developments and Future Plans

2.6 GlaxoSmithKline (US)

2.6.1 GlaxoSmithKline (US) Details

2.6.2 GlaxoSmithKline (US) Major Business

2.6.3 GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions

2.6.4 GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 GlaxoSmithKline (US) Recent Developments and Future Plans

2.7 Alimera Sciences (US)

2.7.1 Alimera Sciences (US) Details

2.7.2 Alimera Sciences (US) Major Business

2.7.3 Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions

2.7.4 Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Alimera Sciences (US) Recent Developments and Future Plans

2.8 StemCell (Canada)

2.8.1 StemCell (Canada) Details

2.8.2 StemCell (Canada) Major Business

2.8.3 StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Product and Solutions

2.8.4 StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 StemCell (Canada) Recent Developments and Future Plans

2.9 F. Hoffmann-La Roche (Switzerland)

2.9.1 F. Hoffmann-La Roche (Switzerland) Details

2.9.2 F. Hoffmann-La Roche (Switzerland) Major Business

2.9.3 F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Product and Solutions

2.9.4 F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 F. Hoffmann-La Roche (Switzerland) Recent Developments and Future Plans

2.10 Regeneron Pharmaceutical (US)

2.10.1 Regeneron Pharmaceutical (US) Details

2.10.2 Regeneron Pharmaceutical (US) Major Business

2.10.3 Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions

2.10.4 Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Regeneron Pharmaceutical (US) Recent Developments and Future Plans

2.11 Allergan (Ireland)

2.11.1 Allergan (Ireland) Details

2.11.2 Allergan (Ireland) Major Business

2.11.3 Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Product and Solutions

2.11.4 Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Allergan (Ireland) Recent Developments and Future Plans

2.12 Adverum Biotechnologies (US)

2.12.1 Adverum Biotechnologies (US) Details

2.12.2 Adverum Biotechnologies (US) Major Business

2.12.3 Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions

2.12.4 Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 Adverum Biotechnologies (US) Recent Developments and Future Plans

2.13 Gilead Sciences (US)

2.13.1 Gilead Sciences (US) Details

2.13.2 Gilead Sciences (US) Major Business

2.13.3 Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions

2.13.4 Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Gilead Sciences (US) Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Wet Age Related Macular Degeneration (AMD) Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Wet Age Related Macular Degeneration (AMD) Players Market Share in 2021

3.2.2 Top 10 Wet Age Related Macular Degeneration (AMD) Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Wet Age Related Macular Degeneration (AMD) Players Head Office, Products and Services Provided

3.4 Wet Age Related Macular Degeneration (AMD) Mergers & Acquisitions

3.5 Wet Age Related Macular Degeneration (AMD) New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Wet Age Related Macular Degeneration (AMD) Revenue and Market Share by Type (2017-2022)

4.2 Global Wet Age Related Macular Degeneration (AMD) Market Forecast by Type (2023-2028)

5 Market Size Segment by Age

5.1 Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Age (2017-2022)

5.2 Global Wet Age Related Macular Degeneration (AMD) Market Forecast by Age (2023-2028)

6 North America by Country, by Type, and by Age

6.1 North America Wet Age Related Macular Degeneration (AMD) Revenue by Type (2017-2028)

6.2 North America Wet Age Related Macular Degeneration (AMD) Revenue by Age (2017-2028)

6.3 North America Wet Age Related Macular Degeneration (AMD) Market Size by Country

6.3.1 North America Wet Age Related Macular Degeneration (AMD) Revenue by Country (2017-2028)

6.3.2 United States Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

6.3.3 Canada Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

6.3.4 Mexico Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Age

7.1 Europe Wet Age Related Macular Degeneration (AMD) Revenue by Type (2017-2028)

7.2 Europe Wet Age Related Macular Degeneration (AMD) Revenue by Age (2017-2028)

7.3 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Country

7.3.1 Europe Wet Age Related Macular Degeneration (AMD) Revenue by Country (2017-2028)

7.3.2 Germany Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

7.3.3 France Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

7.3.5 Russia Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

7.3.6 Italy Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Age

8.1 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Revenue by Type (2017-2028)

8.2 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Revenue by Age (2017-2028)

8.3 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Region

8.3.1 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Revenue by Region (2017-2028)

8.3.2 China Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

8.3.3 Japan Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

8.3.4 South Korea Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

8.3.5 India Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

8.3.7 Australia Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Age

9.1 South America Wet Age Related Macular Degeneration (AMD) Revenue by Type (2017-2028)

9.2 South America Wet Age Related Macular Degeneration (AMD) Revenue by Age (2017-2028)

9.3 South America Wet Age Related Macular Degeneration (AMD) Market Size by Country

9.3.1 South America Wet Age Related Macular Degeneration (AMD) Revenue by Country (2017-2028)

9.3.2 Brazil Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

9.3.3 Argentina Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Age

10.1 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Revenue by Type (2017-2028)

10.2 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Revenue by Age (2017-2028)

10.3 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Country

10.3.1 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Revenue by Country (2017-2028)

10.3.2 Turkey Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

10.3.4 UAE Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Wet Age Related Macular Degeneration (AMD) Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Wet Age Related Macular Degeneration (AMD) Revenue by Age, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Wet Age Related Macular Degeneration (AMD) Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Wet Age Related Macular Degeneration (AMD) Revenue (USD Million) by Region (2017-2022)

Table 5. Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Region (2023-2028)

Table 6. Novartis International (Switzerland) Corporate Information, Head Office, and Major Competitors

Table 7. Novartis International (Switzerland) Major Business

Table 8. Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Product and Solutions

Table 9. Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Bayer (Germany) Corporate Information, Head Office, and Major Competitors

Table 11. Bayer (Germany) Major Business

Table 12. Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Product and Solutions

Table 13. Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Acucela (US) Corporate Information, Head Office, and Major Competitors

Table 15. Acucela (US) Major Business

Table 16. Acucela (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions

Table 17. Acucela (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Neurotech Pharmaceuticals (US) Corporate Information, Head Office, and Major Competitors

Table 19. Neurotech Pharmaceuticals (US) Major Business

Table 20. Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions

Table 21. Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Ophthotech (US) Corporate Information, Head Office, and Major Competitors

Table 23. Ophthotech (US) Major Business

Table 24. Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions

Table 25. Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. GlaxoSmithKline (US) Corporate Information, Head Office, and Major Competitors

Table 27. GlaxoSmithKline (US) Major Business

Table 28. GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions

Table 29. GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Alimera Sciences (US) Corporate Information, Head Office, and Major Competitors

Table 31. Alimera Sciences (US) Major Business

Table 32. Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions

Table 33. Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. StemCell (Canada) Corporate Information, Head Office, and Major Competitors

Table 35. StemCell (Canada) Major Business

Table 36. StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Product and Solutions

Table 37. StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. F. Hoffmann-La Roche (Switzerland) Corporate Information, Head Office, and Major Competitors

Table 39. F. Hoffmann-La Roche (Switzerland) Major Business

Table 40. F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Product and Solutions

Table 41. F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Regeneron Pharmaceutical (US) Corporate Information, Head Office, and Major Competitors

Table 43. Regeneron Pharmaceutical (US) Major Business

Table 44. Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions

Table 45. Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Allergan (Ireland) Corporate Information, Head Office, and Major Competitors

Table 47. Allergan (Ireland) Major Business

Table 48. Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Product and Solutions

Table 49. Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Adverum Biotechnologies (US) Corporate Information, Head Office, and Major Competitors

Table 51. Adverum Biotechnologies (US) Major Business

Table 52. Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions

Table 53. Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Gilead Sciences (US) Corporate Information, Head Office, and Major Competitors

Table 55. Gilead Sciences (US) Major Business

Table 56. Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions

Table 57. Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. Global Wet Age Related Macular Degeneration (AMD) Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 59. Global Wet Age Related Macular Degeneration (AMD) Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 60. Breakdown of Wet Age Related Macular Degeneration (AMD) by Company Type (Tier 1, Tier 2 and Tier 3)

Table 61. Wet Age Related Macular Degeneration (AMD) Players Head Office, Products and Services Provided

Table 62. Wet Age Related Macular Degeneration (AMD) Mergers & Acquisitions in the Past Five Years

Table 63. Wet Age Related Macular Degeneration (AMD) New Entrants and Expansion Plans

Table 64. Global Wet Age Related Macular Degeneration (AMD) Revenue (USD Million) by Type (2017-2022)

Table 65. Global Wet Age Related Macular Degeneration (AMD) Revenue Share by Type (2017-2022)

Table 66. Global Wet Age Related Macular Degeneration (AMD) Revenue Forecast by Type (2023-2028)

Table 67. Global Wet Age Related Macular Degeneration (AMD) Revenue by Age (2017-2022)

Table 68. Global Wet Age Related Macular Degeneration (AMD) Revenue Forecast by Age (2023-2028)

Table 69. North America Wet Age Related Macular Degeneration (AMD) Revenue by Type (2017-2022) & (USD Million)

Table 70. North America Wet Age Related Macular Degeneration (AMD) Revenue by Type (2023-2028) & (USD Million)

Table 71. North America Wet Age Related Macular Degeneration (AMD) Revenue by Age (2017-2022) & (USD Million)

Table 72. North America Wet Age Related Macular Degeneration (AMD) Revenue by Age (2023-2028) & (USD Million)

Table 73. North America Wet Age Related Macular Degeneration (AMD) Revenue by Country (2017-2022) & (USD Million)

Table 74. North America Wet Age Related Macular Degeneration (AMD) Revenue by Country (2023-2028) & (USD Million)

Table 75. Europe Wet Age Related Macular Degeneration (AMD) Revenue by Type (2017-2022) & (USD Million)

Table 76. Europe Wet Age Related Macular Degeneration (AMD) Revenue by Type (2023-2028) & (USD Million)

Table 77. Europe Wet Age Related Macular Degeneration (AMD) Revenue by Age (2017-2022) & (USD Million)

Table 78. Europe Wet Age Related Macular Degeneration (AMD) Revenue by Age (2023-2028) & (USD Million)

Table 79. Europe Wet Age Related Macular Degeneration (AMD) Revenue by Country (2017-2022) & (USD Million)

Table 80. Europe Wet Age Related Macular Degeneration (AMD) Revenue by Country (2023-2028) & (USD Million)

Table 81. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Revenue by Type (2017-2022) & (USD Million)

Table 82. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Revenue by Type (2023-2028) & (USD Million)

Table 83. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Revenue by Age (2017-2022) & (USD Million)

Table 84. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Revenue by Age (2023-2028) & (USD Million)

Table 85. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Revenue by Region (2017-2022) & (USD Million)

Table 86. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Revenue by Region (2023-2028) & (USD Million)

Table 87. South America Wet Age Related Macular Degeneration (AMD) Revenue by Type (2017-2022) & (USD Million)

Table 88. South America Wet Age Related Macular Degeneration (AMD) Revenue by Type (2023-2028) & (USD Million)

Table 89. South America Wet Age Related Macular Degeneration (AMD) Revenue by Age (2017-2022) & (USD Million)

Table 90. South America Wet Age Related Macular Degeneration (AMD) Revenue by Age (2023-2028) & (USD Million)

Table 91. South America Wet Age Related Macular Degeneration (AMD) Revenue by Country (2017-2022) & (USD Million)

Table 92. South America Wet Age Related Macular Degeneration (AMD) Revenue by Country (2023-2028) & (USD Million)

Table 93. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Revenue by Type (2017-2022) & (USD Million)

Table 94. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Revenue by Type (2023-2028) & (USD Million)

Table 95. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Revenue by Age (2017-2022) & (USD Million)

Table 96. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Revenue by Age (2023-2028) & (USD Million)

Table 97. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Revenue by Country (2017-2022) & (USD Million)

Table 98. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Wet Age Related Macular Degeneration (AMD) Picture

Figure 2. Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Type in 2021

Figure 3. Wet Age-Related Macular Degeneration (Wet AMD)

Figure 4. Dry Age-Related Macular Degeneration (Dry AMD)

Figure 5. Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Age in 2021

Figure 6. Above 75 Years Picture

Figure 7. Above 60 Years Picture

Figure 8. Above 40 Years Picture

Figure 9. Global Wet Age Related Macular Degeneration (AMD) Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 10. Global Wet Age Related Macular Degeneration (AMD) Revenue and Forecast (2017-2028) & (USD Million)

Figure 11. Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Region (2017-2028)

Figure 12. Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Region in 2021

Figure 13. North America Wet Age Related Macular Degeneration (AMD) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 14. Europe Wet Age Related Macular Degeneration (AMD) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 15. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 16. South America Wet Age Related Macular Degeneration (AMD) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. Middle East and Africa Wet Age Related Macular Degeneration (AMD) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. Wet Age Related Macular Degeneration (AMD) Market Drivers

Figure 19. Wet Age Related Macular Degeneration (AMD) Market Restraints

Figure 20. Wet Age Related Macular Degeneration (AMD) Market Trends

Figure 21. Novartis International (Switzerland) Recent Developments and Future Plans

Figure 22. Bayer (Germany) Recent Developments and Future Plans

Figure 23. Acucela (US) Recent Developments and Future Plans

Figure 24. Neurotech Pharmaceuticals (US) Recent Developments and Future Plans

Figure 25. Ophthotech (US) Recent Developments and Future Plans

Figure 26. GlaxoSmithKline (US) Recent Developments and Future Plans

Figure 27. Alimera Sciences (US) Recent Developments and Future Plans

Figure 28. StemCell (Canada) Recent Developments and Future Plans

Figure 29. F. Hoffmann-La Roche (Switzerland) Recent Developments and Future Plans

Figure 30. Regeneron Pharmaceutical (US) Recent Developments and Future Plans

Figure 31. Allergan (Ireland) Recent Developments and Future Plans

Figure 32. Adverum Biotechnologies (US) Recent Developments and Future Plans

Figure 33. Gilead Sciences (US) Recent Developments and Future Plans

Figure 34. Global Wet Age Related Macular Degeneration (AMD) Revenue Share by Players in 2021

Figure 35. Wet Age Related Macular Degeneration (AMD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 36. Global Top 3 Players Wet Age Related Macular Degeneration (AMD) Revenue Market Share in 2021

Figure 37. Global Top 10 Players Wet Age Related Macular Degeneration (AMD) Revenue Market Share in 2021

Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 39. Global Wet Age Related Macular Degeneration (AMD) Revenue Share by Type in 2021

Figure 40. Global Wet Age Related Macular Degeneration (AMD) Market Share Forecast by Type (2023-2028)

Figure 41. Global Wet Age Related Macular Degeneration (AMD) Revenue Share by Age in 2021

Figure 42. Global Wet Age Related Macular Degeneration (AMD) Market Share Forecast by Age (2023-2028)

Figure 43. North America Wet Age Related Macular Degeneration (AMD) Sales Market Share by Type (2017-2028)

Figure 44. North America Wet Age Related Macular Degeneration (AMD) Sales Market Share by Age (2017-2028)

Figure 45. North America Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Country (2017-2028)

Figure 46. United States Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 47. Canada Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 48. Mexico Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 49. Europe Wet Age Related Macular Degeneration (AMD) Sales Market Share by Type (2017-2028)

Figure 50. Europe Wet Age Related Macular Degeneration (AMD) Sales Market Share by Age (2017-2028)

Figure 51. Europe Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Country (2017-2028)

Figure 52. Germany Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. France Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. United Kingdom Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. Russia Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. Italy Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Sales Market Share by Type (2017-2028)

Figure 58. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Sales Market Share by Age (2017-2028)

Figure 59. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Region (2017-2028)

Figure 60. China Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. Japan Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. South Korea Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. India Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. Southeast Asia Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. Australia Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. South America Wet Age Related Macular Degeneration (AMD) Sales Market Share by Type (2017-2028)

Figure 67. South America Wet Age Related Macular Degeneration (AMD) Sales Market Share by Age (2017-2028)

Figure 68. South America Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Country (2017-2028)

Figure 69. Brazil Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. Argentina Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. Middle East and Africa Wet Age Related Macular Degeneration (AMD) Sales Market Share by Type (2017-2028)

Figure 72. Middle East and Africa Wet Age Related Macular Degeneration (AMD) Sales Market Share by Age (2017-2028)

Figure 73. Middle East and Africa Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Country (2017-2028)

Figure 74. Turkey Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Saudi Arabia Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. UAE Wet Age Related Macular Degeneration (AMD) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 77. Methodology

Figure 78. Research Process and Data Source

License Type

Quick Contact

Our Clients

Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz